Nurix Therapeutics, Inc. (NRIX) · INSIDERData sourcesSEC Form 43h ago
House PTR3h ago
SEC 13F3h ago
Robinhood Chain3h ago
Public companyNurix Therapeutics, Inc.
NRIXCIK 0001549595
Price$16.14
1 year+28.9%
Disclosed transactions60
Buys / sells0 / 17
Max Insider Score35
Connections with evidence7
NRIX · disclosed activity on price
| Score | Actor | Security | Side | Value | Executed | Disclosed | Lag | Source | Evidence |
|---|
| 3 | RCRing ChristineChief Legal Officer | NRIXNurix Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $50K 5,786 sh | Nov 2, 2026 | Nov 4, 2026 |
| 0 | RCRing ChristineChief Legal Officer | NRIXNurix Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 5,786 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC Form 4 | |
| 18 | VHvan Houte HansChief Financial Officer | NRIXNurix Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $51K 3,300 sh | Nov 4, 2026 | Nov 4, 2026 traded Nov 4, 2026 | +0d | SEC Form 4 | |
| 11 | VHvan Houte HansChief Financial Officer | NRIXNurix Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $24K 1,469 sh | Nov 4, 2026 | Nov 4, 2026 traded Nov 4, 2026 | +0d | SEC Form 4 | |
| 19 | RCRing ChristineChief Legal Officer | NRIXNurix Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $245K 9,527 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC Form 4 | |
| 23 | RCRing ChristineChief Legal Officer | NRIXNurix Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $158K 6,113 sh | Nov 3, 2026 | Nov 4, 2026 traded Nov 3, 2026 | +1d | SEC Form 4 | |
| 12 | RCRing ChristineChief Legal Officer | NRIXNurix Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $29K 1,075 sh | Nov 2, 2026 | Nov 4, 2026 traded Nov 2, 2026 | +2d | SEC Form 4 | |
| 0 | HGHansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 3,750 sh | Oct 30, 2026 | Nov 2, 2026 traded Oct 30, 2026 | +3d | SEC Form 4 | |
| 17 | VHvan Houte HansChief Financial Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 3,750 sh | Oct 30, 2026 | Nov 2, 2026 traded Oct 30, 2026 | +3d | SEC Form 4 | |
| 0 | HGHansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 2,859 sh | Oct 30, 2026 | Nov 2, 2026 traded Oct 30, 2026 | +3d | SEC Form 4 | |
| 35 | RCRing ChristineChief Legal Officer | NRIXNurix Therapeutics, Inc. Open-market sale | SELL | $104K 3,957 sh | Oct 30, 2026 | Nov 2, 2026 traded Oct 30, 2026 | +3d | SEC Form 4 | |
| 4 | HGHansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 3,750 sh | Oct 30, 2026 | Nov 2, 2026 traded Oct 30, 2026 | +3d | SEC Form 4 | |
| 0 | HGHansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 2,859 sh | Oct 30, 2026 | Nov 2, 2026 traded Oct 30, 2026 | +3d | SEC Form 4 | |
| 34 | VHvan Houte HansChief Financial Officer | NRIXNurix Therapeutics, Inc. Open-market sale | SELL | $74K 2,834 sh | Oct 30, 2026 | Nov 2, 2026 traded Oct 30, 2026 | +3d | SEC Form 4 | |
| 10 | RCRing ChristineChief Legal Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 2,859 sh | Oct 30, 2026 | Nov 2, 2026 traded Oct 30, 2026 | +3d | SEC Form 4 | |
| 9 | VHvan Houte HansChief Financial Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 3,573 sh | Oct 30, 2026 | Nov 2, 2026 traded Oct 30, 2026 | +3d | SEC Form 4 | |
| 9 | VHvan Houte HansChief Financial Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 3,573 sh | Oct 30, 2026 | Nov 2, 2026 traded Oct 30, 2026 | +3d | SEC Form 4 | |
| 9 | VHvan Houte HansChief Financial Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 3,750 sh | Oct 30, 2026 | Nov 2, 2026 traded Oct 30, 2026 | +3d | SEC Form 4 | |
| 10 | RCRing ChristineChief Legal Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 2,859 sh | Oct 30, 2026 | Nov 2, 2026 traded Oct 30, 2026 | +3d | SEC Form 4 | |
| 11 | HGHansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $104K 3,957 sh | Oct 30, 2026 | Nov 2, 2026 traded Oct 30, 2026 | +3d | SEC Form 4 | |
| 0 | HGHansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 3,573 sh | Oct 30, 2026 | Nov 2, 2026 traded Oct 30, 2026 | +3d | SEC Form 4 | |
| 0 | HGHansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $2,701 1,452 sh | Nov 2, 2026 | Nov 2, 2026 traded Nov 2, 2026 | +0d | SEC Form 4 | |
| 9 | VHvan Houte HansChief Financial Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 2,859 sh | Oct 30, 2026 | Nov 2, 2026 traded Oct 30, 2026 | +3d | SEC Form 4 | |
| 13 | VHvan Houte HansChief Financial Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 2,859 sh | Oct 30, 2026 | Nov 2, 2026 traded Oct 30, 2026 | +3d | SEC Form 4 | |
| 6 | RCRing ChristineChief Legal Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 3,573 sh | Oct 30, 2026 | Nov 2, 2026 traded Oct 30, 2026 | +3d | SEC Form 4 | |
| 0 | HGHansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 1,452 sh | Nov 2, 2026 | Nov 2, 2026 traded Nov 2, 2026 | +0d | SEC Form 4 | |
| 8 | HGHansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $39K 1,452 sh | Nov 2, 2026 | Nov 2, 2026 traded Nov 2, 2026 | +0d | SEC Form 4 | |
| 14 | RCRing ChristineChief Legal Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 3,750 sh | Oct 30, 2026 | Nov 2, 2026 traded Oct 30, 2026 | +3d | SEC Form 4 | |
| 10 | RCRing ChristineChief Legal Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 3,573 sh | Oct 30, 2026 | Nov 2, 2026 traded Oct 30, 2026 | +3d | SEC Form 4 | |
| 10 | RCRing ChristineChief Legal Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 3,750 sh | Oct 30, 2026 | Nov 2, 2026 traded Oct 30, 2026 | +3d | SEC Form 4 | |
| 0 | HGHansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 3,573 sh | Oct 30, 2026 | Nov 2, 2026 traded Oct 30, 2026 | +3d | SEC Form 4 | |
| 0 | HGHansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $2,701 1,452 sh | Oct 15, 2026 | Oct 15, 2026 traded Oct 15, 2026 | +0d | SEC Form 4 | |
| 1 | HGHansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $36K 1,452 sh | Oct 15, 2026 | Oct 15, 2026 traded Oct 15, 2026 | +0d | SEC Form 4 | |
| 0 | HGHansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 1,452 sh | Oct 15, 2026 | Oct 15, 2026 traded Oct 15, 2026 | +0d | SEC Form 4 | |
| 0 | HGHansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 1,452 sh | Sep 1, 2026 | Sep 1, 2026 traded Sep 1, 2026 | +0d | SEC Form 4 | |
| 0 | HGHansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $2,701 1,452 sh | Sep 1, 2026 | Sep 1, 2026 traded Sep 1, 2026 | +0d | SEC Form 4 | |
| 1 | HGHansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $37K 1,452 sh | Sep 1, 2026 | Sep 1, 2026 traded Sep 1, 2026 | +0d | SEC Form 4 | |
| 7 | RCRing ChristineChief Legal Officer | NRIXNurix Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $97K 13.3K sh | Jun 25, 2026 | Jun 25, 2026 traded Jun 25, 2026 | +0d | SEC Form 4 | |
| 9 | HGHansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $108K 5,394 sh | Jun 25, 2026 | Jun 25, 2026 traded Jun 25, 2026 | +0d | SEC Form 4 | |
| 21 | RCRing ChristineChief Legal Officer | NRIXNurix Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $581K 28.9K sh | Jun 25, 2026 | Jun 25, 2026 traded Jun 25, 2026 | +0d | SEC Form 4 | |
| 7 | RCRing ChristineChief Legal Officer | NRIXNurix Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $136K 15.6K sh | Jun 25, 2026 | Jun 25, 2026 traded Jun 25, 2026 | +0d | SEC Form 4 | |
| 0 | RCRing ChristineChief Legal Officer | NRIXNurix Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 15.6K sh | Jun 25, 2026 | Jun 25, 2026 traded Jun 25, 2026 | +0d | SEC Form 4 | |
| 0 | RCRing ChristineChief Legal Officer | NRIXNurix Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 13.3K sh | Jun 25, 2026 | Jun 25, 2026 traded Jun 25, 2026 | +0d | SEC Form 4 | |
| 9 | SCSaltzman Edward CDirector | NRIXNurix Therapeutics, Inc. Grant or award | A | — 31.3K sh | May 15, 2026 | May 15, 2026 traded May 15, 2026 | +0d | SEC Form 4 | |
| 15 | RCRing ChristineChief Legal Officer | NRIXNurix Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $90K 5,394 sh | May 1, 2026 | May 1, 2026 traded May 1, 2026 | +0d | SEC Form 4 | |
| 27 | VHvan Houte HansChief Financial Officer | NRIXNurix Therapeutics, Inc. Open-market sale | SELL | $40K 2,388 sh | Apr 30, 2026 | Apr 30, 2026 traded Apr 30, 2026 | +0d | SEC Form 4 | |
| 9 | VHvan Houte HansChief Financial Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 3,750 sh | Apr 30, 2026 | Apr 30, 2026 traded Apr 30, 2026 | +0d | SEC Form 4 | |
| 6 | RCRing ChristineChief Legal Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 2,858 sh | Apr 30, 2026 | Apr 30, 2026 traded Apr 30, 2026 | +0d | SEC Form 4 | |
| 31 | RCRing ChristineChief Legal Officer | NRIXNurix Therapeutics, Inc. Open-market sale | SELL | $53K 3,214 sh | Apr 30, 2026 | Apr 30, 2026 traded Apr 30, 2026 | +0d | SEC Form 4 | |
| 6 | RCRing ChristineChief Legal Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 2,858 sh | Apr 30, 2026 | Apr 30, 2026 traded Apr 30, 2026 | +0d | SEC Form 4 | |
| 2 | RCRing ChristineChief Legal Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 2,000 sh | Apr 30, 2026 | Apr 30, 2026 traded Apr 30, 2026 | +0d | SEC Form 4 | |
| 5 | HGHansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 3,750 sh | Apr 30, 2026 | Apr 30, 2026 traded Apr 30, 2026 | +0d | SEC Form 4 | |
| 9 | VHvan Houte HansChief Financial Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 2,858 sh | Apr 30, 2026 | Apr 30, 2026 traded Apr 30, 2026 | +0d | SEC Form 4 | |
| 6 | RCRing ChristineChief Legal Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 3,750 sh | Apr 30, 2026 | Apr 30, 2026 traded Apr 30, 2026 | +0d | SEC Form 4 | |
| 5 | VHvan Houte HansChief Financial Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 2,000 sh | Apr 30, 2026 | Apr 30, 2026 traded Apr 30, 2026 | +0d | SEC Form 4 | |
| 6 | RCRing ChristineChief Legal Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 2,000 sh | Apr 30, 2026 | Apr 30, 2026 traded Apr 30, 2026 | +0d | SEC Form 4 | |
| 9 | HGHansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 2,858 sh | Apr 30, 2026 | Apr 30, 2026 traded Apr 30, 2026 | +0d | SEC Form 4 | |
| 10 | RCRing ChristineChief Legal Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 3,750 sh | Apr 30, 2026 | Apr 30, 2026 traded Apr 30, 2026 | +0d | SEC Form 4 | |
| 13 | VHvan Houte HansChief Financial Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 3,750 sh | Apr 30, 2026 | Apr 30, 2026 traded Apr 30, 2026 | +0d | SEC Form 4 | |
| 30 | HGHansen GwennChief Scientific Officer | NRIXNurix Therapeutics, Inc. Open-market sale | SELL | $53K 3,214 sh | Apr 30, 2026 | Apr 30, 2026 traded Apr 30, 2026 | +0d | SEC Form 4 | |
Chief Scientific Officer · Jan 30, 2026
Planned sales and 5% stakes
Form 144, 13D and 13G- FMFMR LLCPassive holder · crossed on Sep 30, 2026 · 4.35M shares4.2% of class13G amendment · filed Nov 5, 2026
- JHJOHANNES VAN HOUTEOfficer · sale around Nov 4, 2026 · 4,769 shares · 10b5-1 plan$123KForm 144 · filed Nov 4, 2026
- CRCHRISTINE RINGOfficer · sale around Nov 3, 2026 · 6,113 shares · 10b5-1 plan$157KForm 144 · filed Nov 3, 2026
- CRCHRISTINE RINGOfficer · sale around Nov 2, 2026 · 10.6K shares · 10b5-1 plan$284KForm 144 · filed Nov 2, 2026